Key terms
About AUPH
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AUPH news
Apr 16
11:38am ET
Aurinia Pharmaceuticals to Present at Investor Conference
Apr 15
6:38am ET
Aurinia Pharmaceuticals Announces Q1 Results Date
Apr 09
6:37am ET
Aurinia Pharma to Connect at Healthcare Investor Event
Mar 01
11:55am ET
Aurinia Pharmaceuticals: Strong Buy Rating Amidst Share Repurchase and Promising LUPKYNIS Prospects
Feb 29
4:23pm ET
Aurinia Pharmaceuticals Announces Executive R&D Leadership Change
Feb 29
9:18am ET
Aurinia Pharmaceuticals Launches Share Buyback Plan
Feb 27
9:09am ET
Aurinia Pharmaceuticals Engages Investors at March Conferences
Feb 22
6:30am ET
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN) and Aurinia Pharmaceuticals (AUPH)
Feb 22
6:13am ET
H.C. Wainwright cuts Aurinia target, says 28% selloff overdone
Feb 20
12:45pm ET
Aurinia Pharmaceuticals call volume above normal and directionally bullish
Feb 18
11:47pm ET
Aurinia Pharmaceuticals: A Buy Rating on Strong Lupkynis Sales and Streamlined Operations
Feb 16
1:02am ET
New Corporate Activity and Growth Risk for Aurinia Pharmaceuticals – What’s the Latest?
Feb 15
12:20pm ET
Analysts Are Bullish on These Healthcare Stocks: Valneva (VALN), Aurinia Pharmaceuticals (AUPH)
Feb 15
6:22am ET
Aurinia Pharmaceuticals Announces Strategic Review Outcomes and Buyback Program
Feb 15
6:19am ET
Aurinia Pharmaceuticals sees 2024 revenue $200M-$220M, consensus $217.87M
Feb 15
6:16am ET
Aurinia Pharmaceuticals reports Q4 EPS (19c), consensus (16c)
Jan 18
11:25am ET
Aurinia Pharmaceuticals call volume above normal and directionally bullish
No recent press releases are available for AUPH
AUPH Financials
Key terms
Ad Feedback
AUPH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AUPH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range